Abstract | ADVERSE EVENT: DRUGS IMPLICATED: THE PATIENT: EVIDENCE THAT LINKS THE DRUG TO THE EVENT: The interaction was confirmed by a decrease in abiraterone exposure >2-fold (area-under-the-curve and trough levels). After discontinuation of carbamazepine therapy, the abiraterone exposure normalized. No alternative causes were found that explain the decrease in abiraterone exposure. MECHANISM: IMPLICATIONS FOR THERAPY: Clinicians and pharmacists should be aware of this clinically relevant interaction. The national drug-drug interaction checker does not warn for this interaction, whereas both the Lexicomp® and Micromedex® advice to avoid if possible or to increase the abiraterone dose frequency to twice daily. Carbamazepine should not be combined with abiraterone to avoid underexposure and suboptimal therapy. Therapeutic drug monitoring of abiraterone is useful to guide therapy when drug-drug interactions cannot be avoided.
|
Authors | Guillemette E Benoist, Maarten J van der Doelen, Rob Ter Heine, Nielka P van Erp, Niven Mehra |
Journal | British journal of clinical pharmacology
(Br J Clin Pharmacol)
Vol. 84
Issue 5
Pg. 1064-1067
(05 2018)
ISSN: 1365-2125 [Electronic] England |
PMID | 29384591
(Publication Type: Case Reports)
|
Copyright | © 2018 The British Pharmacological Society. |
Chemical References |
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Cytochrome P-450 CYP3A Inducers
- Carbamazepine
- Prednisolone
- Abiraterone Acetate
|
Topics |
- Abiraterone Acetate
(blood, pharmacokinetics)
- Aged
- Analgesics, Non-Narcotic
(pharmacology, therapeutic use)
- Antineoplastic Agents
(blood, pharmacokinetics)
- Carbamazepine
(pharmacology, therapeutic use)
- Cytochrome P-450 CYP3A Inducers
(pharmacology)
- Drug Interactions
- Facial Nerve Diseases
(drug therapy)
- Humans
- Male
- Prednisolone
(therapeutic use)
- Prostatic Neoplasms, Castration-Resistant
(drug therapy)
|